Every 8-K that Virios Therapeutics, Inc. (VIRI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VIRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIRI filings page.
Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.
The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.